Regulatory Routine +

Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging

FDA Clearance Confirms Timeline, But Cash Burn Threatens Commercial Launch Viability

By The Northwire Desk — AI Analysis Apr 20, 2026 · 07:00 CNVI · 0.425 Conavi Medical Corp.

Executive Summary

On April 20, 2026, Conavi Medical announced it received U.S. FDA 510(k) clearance for its next-generation hybrid IVUS-OCT imaging system (Novasight Hybrid).
The clearance enables the company to initiate a commercial launch in the United States, targeted for the second half of 2026.
The system integrates intravascular ultrasound and optical coherence tomography into a single workflow, allowing simultaneous visualization of vessel structures.
This announcement follows a $12 million equity offering closed on January 13, 2026, which was explicitly earmarked for FDA clearance efforts and U.S. market launch preparations.
Previous guidance provided in February 2026 anticipated this clearance within the first half of 2026; the April announcement confirms adherence to that timeline.

Material Impact

Expectation vs. Reality: The news is consistent with previous guidance issued on February 26, 2026, which stated an anticipated clearance in H1 2026. As such, this does not represent a surprise upside event but rather the execution of a previously communicated roadmap.
Commercial Viability: While regulatory risk is removed for the U.S. market, the company faces significant commercialization risks. The cash runway is tight relative to the capital required for a full-scale launch (sales force, marketing, inventory).
Price Impact: The stock price ($0.43) remains below the January 2026 offering price of $0.45. Investors who participated in the recent financing are currently underwater, which may limit upside momentum until the share price reclaims the $0.45 level.
Risk Profile: The clearance is a necessary step for revenue generation but does not guarantee commercial success or immediate profitability given the high operating burn rate observed in Q1 FY26 ($5.1 million operating loss).

CNVI · Price

Company Overview

Company Profile: Conavi Medical Corp. is a medical device company focused on intravascular imaging technologies for coronary interventions.
Flagship Project: The Novasight Hybrid™ system, which combines IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography).
Development Status: Next-generation system received FDA 510(k) clearance in April 2026. First-generation system is already cleared in U.S., Canada, China, and Japan.
Market Opportunity: Targeting the coronary intravascular imaging market estimated at over $4 billion annually.

More from Conavi Medical Corp.